儿童肺炎支原体肺炎治疗进展  

Therapeutic progress of Mycoplasma pneumoniae pneumonia in children

作　　者：陈志敏[1] 求伟玲[1] Chen Zhimin;Qiu Weiling(Department of Pulmonology,Children′s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]国家儿童健康与疾病临床医学研究中心,浙江大学医学院附属儿童医院呼吸内科,杭州310052

出　　处：《中华实用儿科临床杂志》2021年第16期1214-1217,共4页Chinese Journal of Applied Clinical Pediatrics

摘　　要：肺炎支原体是儿童社区获得性肺炎的重要病原。虽然肺炎支原体感染具有一定的自限性,但近年来重症或难治性肺炎支原体肺炎病例报道显著增多,患儿病情重、病程延长,且易出现肺内和肺外并发症,部分可遗留后遗症,对治疗提出了挑战。现就儿童肺炎支原体肺炎的治疗进展进行阐述。Mycoplasma pneumoniae is an important pathogen of community-acquired pneumonia in children.Although Mycoplasma pneumoniae infection is likely to be self-limited,severe or refractory cases of Mycoplasma pneumoniae pneumonia are increasing,with severe condition and prolonged course,prone to pulmonary and extra-pulmonary complications,some with sequelae,which challenges the treatment.Here,we reviewed the therapeutic progress of Mycoplasma pneumoniae pneumonia.

关 键 词：肺炎支原体肺炎 治疗 进展 儿童 

分 类 号：R725.6[医药卫生—儿科]